Fig. 01 The new fluocinolone acetonide (FA) 0.18 mg intravitreal implant uses a non-bioerodible, micro-insert platform that is designed to release a daily FA dose of 0.25 mcg over 3 years. David Callanan, MD, noted the minute size of the implant probably explains why the majority of patients do not seem to be aware of its presence in the eye. (Image courtesy of EyePoint Pharmaceuticals)

Fig. 02 The micro-insert is injected into the vitreous through the pars plana using a preloaded sterile applicator fitted with a 25-gauge needle. The injection is done in an in-office procedure. (Image courtesy of EyePoint Pharmaceuticals)